Related references
Note: Only part of the references are listed.MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-κB signaling
Rebecca T. Marquez et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2010)
Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system
Erich M. Ehlert et al.
BMC NEUROSCIENCE (2010)
Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver
Dirk Grimm et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivo
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells
Jeffrey W. Hewett et al.
HUMAN MOLECULAR GENETICS (2008)
Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic
Jeffery C. Giering et al.
MOLECULAR THERAPY (2008)
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
Jodi L. McBride et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration
Trinna L. Cuellar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Technology Insight: therapeutic RNA interference - how far from the neurology clinic?
Pedro Gonzalez-Alegre et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
The inherited dystonias
Pedro Gonzalez-Alegre
SEMINARS IN NEUROLOGY (2007)
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Dirk Grimm et al.
NATURE (2006)
RNAi blocks DYT1 mutant torsinA inclusions in neurons
N Kock et al.
NEUROSCIENCE LETTERS (2006)
Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope
RE Goodchild et al.
NEURON (2005)
Silencing primary dystonia: Lentiviral-mediated RNA interference therapy for DYT1 dystonia
P Gonzalez-Alegre et al.
JOURNAL OF NEUROSCIENCE (2005)
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice
E Rodriguez-Lebron et al.
MOLECULAR THERAPY (2005)
DARPP-32 genomic fragments drive Cre expression in postnatal striatum
AI Bogush et al.
GENESIS (2005)
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model
SQ Harper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated ΔE-torsinA mutant
GE Torres et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors
Z Sandalon et al.
JOURNAL OF VIROLOGY (2004)
Toward therapy for DYT1 dystonia: Allele-specific silencing of mutant TorsinA
P Gonzalez-Alegre et al.
ANNALS OF NEUROLOGY (2003)
Regional and strain-specific gene expression mapping in the adult mouse brain
R Sandberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
